Lawrence Bock

Special Limited Partner, Lux Capital Management

Larry Bock, is a Special Limited Partner and currently serves as Chairman of LUX Ventures’ Advisory Board of industry experts advising the Investment Team. Mr. Bock is a Co-Founder and Executive Chairman of Nanosys, Inc. Prior to Nanosys, he was a managing general partner of CW Group, a life sciences venture capital fund. Mr. Bock was also a general partner of Avalon Ventures, a seed stage venture capital firm. Mr. Bock has been the founder and initial chief executive officer of Metra Biosystems, Inc., Neurocrine Biosciences, Inc. (NASDAQ: NBIX - neuroimmunology), Pharmacopeia, Inc. (NASDAQ: PCOP – combinatorial chemistry), Argonaut Technologies, Inc (NASDAQ: AGNT – combinatorial chemistry), and Caliper Technologies Corp (NASDAQ: CALP – lab-on-a-chip). Mr. Bock was also a co-founder of ARIAD Pharmaceuticals, Inc (NASDAQ: ARIA – intra cellular signal transduction), Athena Neurosciences (NASDAQ: ATHN, acquired by Elan Pharmaceuticals for $700M – molecular neurobiology) Inc., GenPharm International (acquired by MedaRx– transgenic animals), Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX – rational drug design), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX – molecular oncology) and Illumina, Inc. (NASDAQ: ILMN – array based optical sensors). He holds a B.A. in Liberal Arts from Bowdoin College and an M.B.A. from the Anderson School at the University of California, Los Angeles.